Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist, and Executive Director of Employer Services at the City of Hope Comprehensive Cancer Center in Duarte, CA.

Webinar by Dr. Lecia Sequist on Acquired Resistance to Oral EGFR Inhibitors in Advanced NSCLC
Wed, 02/23/2011 - 13:45
Howard (Jack) West, MD, Associate Clinical Professor, Medical Oncology, Executive Director, Employer Services, Founder, President and CEO of GRACE

Two weeks from now (March 9, 3 PM EST/noon PST), Dr. Lecia Sequist of Massachusetts General Hospital will lead a free online webinar that is a joint program between GRACE and LUNGevity, on the topic of "Acquired Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs): What We Know Now, and How We’re Moving Forward", to be followed by an interactive Q&A session.

lecia-seqist1 Dr. Sequist is a medical oncologist and Assistant Professor of Medicine, Harvard Medical School; Center for Thoracic Cancers, Massachusetts General Hospital Cancer Center, and she is also one of the people at the forefront of management questions for patients with an activating EGFR mutation.

Some highlight issues we'll plan to cover:

1. What is known about the timing of development of acquired resistance to oral EGFR TKIs?

2. Is there anything known about ways to postpone acquired resistance?

3. Once progression is documented, is there anything to be done to restore/improve activity of these agents?

4. Are there data to speak to concept of continuing an EGFR TKI while adding chemo or some other agent, vs. stopping it at progression and switching to new therapy?

5. What is known about mechanisms of acquired resistance and any differences in clinical behavior and outcomes among these?

6. What practically useful information can be gained from re-biopsy at progression?

7. What are practical barriers to re-biopsy at progression?

8. What clinical trials are available for motivated patients?

Although this topic is most directly relevant to the minority of lung cancer patients with an activating EGFR mutation, the question of how to manage acquired resistance after a good initial response is a timely issue that is becoming increasingly relevant in our increasingly molecularly-defined approach to lung cancer.

For those interested and able to attend the live program, you can register here (registration info to be shared between GRACE and LUNGevity). For those who can't attend the live event or who don't want to worry about taking notes, we'll make this content available as a free podcast (audio or video) for everyone.

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

Hi snickerdoodle, I'm sorry you're going through this worry. Cea levels for nsclc don't really inform treatment decisions. They sometimes forewarn the coming of progression but sometimes progression doesn't follow a...

I appreciate the comments. I also want to correct my mistake in CEA level- I forgot the decimal. In the past year, my level has increased from 4.7 to 28.3, NOT...

Hi Rick and welcome to Grace. I'm sorry you're going through this. Ethically or legally we can't comment on reports.
Cancer and infection look alike on film and they both cause...

I just saw this link on our fb page. Scanxiety is unfortunately real enough to have a term everyone knows.  Cancer or no (and I'm going for no) you can use...

I completely understand about not being able to comment on reports, I appreciate the support and positive thinking. I am at peace now and am going to remain hopeful-positive until we...

I hope you keep us posted. and Waiting is always the hardest part.

Recent Comments

CEA 28.3
By snickerdoodle531 on Wed, 06/22/2022 - 16:05
Hi snickerdoodle, I'm sorry…
By snickerdoodle531 on Wed, 06/22/2022 - 10:52
Read through this thread. As…
By JanineT Forum … on Wed, 06/15/2022 - 11:20
Tagrix vs Tagrisso
By JanineT Forum … on Tue, 06/14/2022 - 23:25